

Contents

Foreword IX

Acknowledgment XV

Preface XVII

List of Contributors XIX

Part One Disease Burden, Current Treatments, Medical Needs, and Strategic Approaches 1

- 1 Visceral Leishmaniasis – Current Treatments and Needs 3
*Poonam Salotra, Ruchi Singh, and Karin Seifert**
- 2 Chemotherapy of Leishmaniasis: A Veterinary Perspective 17
*María Jesús Corral-Caridad and José María Alunda**
- 3 Pharmacological Metabolomics in Trypanosomes 37
*Darren J. Creek, Isabel M. Vincent, and Michael P. Barrett**
- 4 Drug Design and Screening by *In Silico* Approaches 57
*Mattia Mori and Maurizio Botta**
- 5 Computational Approaches and Collaborative Drug Discovery
for Trypanosomal Diseases 81
Sean Ekins and Barry A. Bunin*

Part Two Metabolic Peculiarities in the Trypanosomatid Family Guiding Drug Discovery 103

- 6 Interaction of *Leishmania* Parasites with Host Cells and its Functional
Consequences 105
*Uta Schurig, Anita Masic, and Heidrun Moll**

- 7 **Function of Glycosomes in the Metabolism of Trypanosomatid Parasites and the Promise of Glycosomal Proteins as Drug Targets** 121
Melisa Gualdrón-López, Paul A.M. Michels, Wilfredo Quiñones, Ana J. Cáceres, Luisana Avilán, and Juan-Luis Concepción*
- 8 **Glyoxalase Enzymes in Trypanosomatids** 153
*Marta Sousa Silva, António E.N. Ferreira, Ricardo Gomes, Ana M. Tomás, Ana Ponces Freire, and Carlos Cordeiro**
- 9 **Trypanothione-Based Redox Metabolism of Trypanosomatids** 167
Marcelo A. Comini and Leopold Flohé*
- 10 **Thiol Peroxidases of Trypanosomatids** 201
Helena Castro and Ana M. Tomás*
- 11 **Peroxynitrite as a Cytotoxic Effector Against *Trypanosoma cruzi*: Oxidative Killing and Antioxidant Resistance Mechanisms** 215
*Madia Trujillo, María Noel Alvarez, Lucía Piacenza, Martín Hugo, Gonzalo Peluffo, and Rafael Radi**
- 12 **Selenoproteome of Kinetoplastids** 237
*Alexei V. Lobanov and Vadim N. Gladyshev**
- 13 **Replication Machinery of Kinetoplast DNA** 243
*Rachel Bezalel-Buch, Nurit Yaffe, and Joseph Shlomai**
- 14 **Life and Death of *Trypanosoma brucei*: New Perspectives for Drug Development** 261
*Torsten Barth, Jasmin Stein, Stefan Mogk, Caroline Schönfeld, Bruno K. Kubata, and Michael Duszenko**
- Part Three Validation and Selection of Drug Targets in Kinetoplasts** 279
- 15 **Rational Selection of Anti-Microbial Drug Targets: Unique or Conserved?** 281
*Boris Rodenko and Harry P. de Koning**
- 16 **Drug Targets in Trypanosomal and Leishmanial Pentose Phosphate Pathway** 297
Marcelo A. Comini, Cecilia Ortíz, and Juan José Cazzulo*
- 17 **GDP-Mannose: A Key Point for Target Identification and Drug Design in Kinetoplastids** 315
Sébastien Pomel and Philippe M. Loiseau*

18	Transporters in Anti-Parasitic Drug Development and Resistance	335
	<i>Vincent Delespaux and Harry P. de Koning*</i>	
19	Peptidases in Autophagy are Therapeutic Targets for Leishmaniasis	351
	<i>Roderick A.M. Williams*</i>	
20	Proteases of <i>Trypanosoma brucei</i>	365
	<i>Dietmar Steverding*</i>	
Part Four Examples of Target-Based Approaches and Compounds Under Consideration 383		
21	Screening Approaches Towards Trypanothione Reductase	385
	<i>Mathias Beig, Frank Oellien, R. Luise Krauth-Siegel, and Paul M. Selzer*</i>	
22	Redox-Active Agents in Reactions Involving the Trypanothione/Trypanothione Reductase-based System to Fight Kinetoplastidal Parasites	405
	<i>Thibault Gendron, Don Antoine Lanfranchi, and Elisabeth Davioud-Charvet*</i>	
23	Inhibition of Trypanothione Synthetase as a Therapeutic Concept	429
	<i>Oliver Koch*, Timo Jäger, Leopold Flohé, and Paul M. Selzer</i>	
24	Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase	445
	<i>Stefania Ferrari, Valeria Losasso, Puneet Saxena, and Maria Paola Costi*</i>	
25	Contribution to New Therapies for Chagas Disease	473
	<i>Patricia S. Doyle* and Juan C. Engel</i>	
26	Ergosterol Biosynthesis for the Specific Treatment of Chagas Disease: From Basic Science to Clinical Trials	489
	<i>Julio A. Urbina*</i>	
27	New Developments in the Treatment of Late-Stage Human African Trypanosomiasis	515
	<i>Cyrus J. Bacchi, Robert T. Jacobs, and Nigel Yarlett*</i>	
	Index	531